Company profile
ACLARIS THERAPEUTICS, INC.
NASDAQ:ACRSBiotechnology: Pharmaceutical Preparations
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ESKATA | approved | — | 11 | approved |
| IFIDANCITINIB | phase2 | — | 5 | no active trials |
| LEPZACITINIB | phase2 | — | 1 | no active trials |
| MODZATINIB | phase2 | — | 1 | no active trials |
| ZUNSEMETINIB | phase2 | — | 5 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (33)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03210337 | phase2 | completed | 2017-08-01 | 2018-03-16 | Aclaris Therapeutics, Inc. | A Phase2 of A-101 Topical Solution in Subjects With Common Warts |
| NCT02667275 | phase3 | completed | 2016-01-01 | 2016-10-01 | Aclaris Therapeutics, Inc. | A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis |
| NCT03148691 | phase2 | completed | 2017-05-17 | 2018-02-28 | Aclaris Therapeutics, Inc. | A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis |
| NCT03495817 | phase2 | completed | 2018-03-22 | 2019-10-15 | Aclaris Therapeutics, Inc. | A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution |
| NCT02667236 | phase3 | completed | 2016-01-01 | 2016-10-01 | Aclaris Therapeutics, Inc. | A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis. |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 209305 | 2017-12-14 | NDA | ACLARIS THERAPEUTICS INC | |||||
Loading… | ||||||||